Operetta CLS High-content Imaging System

Operetta CLS 高内涵成像系统

• 批准号: 9274679
• 负责人: JOHN S. LAZO
• 金额: $ 51.6万
• 依托单位: UNIVERSITY OF VIRGINIA
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-03-02 至 2018-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9274679
• 关键词: Automation; Basic Science; Biological; Biomedical Research; Cardiovascular Diseases; Cells; Clinical Research; Communicable Diseases; Data Analyses; Ebola virus; Evaluation; Fluorescence Microscopy; Genes; Image; Individual; Influenza; Kinetics; Malignant Neoplasms; Methods; Mutation; Nerve Degeneration; Obesity; Organism; Peripheral; Pharmaceutical Preparations; Pharmacotherapy; Phase; Positioning Attribute; Research; Research Project Grants; Sampling; Speed; Universities; Virginia; base; drug candidate; fluorescence imaging; human disease; imaging system; instrument; light microscopy; population based; programs; screening; tool

Project Summary/Abstract High-content screening employs an imaging-based platform, which combines the efficacy and speed of high-throughput automation and the power of light microscopy, especially fluorescence microscopy, to simultaneously capture both functional and morphometric information from a large number of samples of cells or organisms following perturbation, such as drug treatment or genetic alteration. High content analysis permits a much more comprehensive quantitative assessment of drug and gene effects than population-based methods, because multiple kinetic and spatial readouts can be simultaneously interrogated in individual cells. This application seeks to fill the gap between a strong demand for high-content screening and the limited capability the University of Virginia can currently offer. The proposed instrument is a PerkinElmer Operetta CLS, a high-content imaging system capable of bright-field, phase-contrast, and wide-field and spinning-disc confocal fluorescence imaging. The acquisition will immediately benefit a wide range of biomedical research projects covering infectious diseases such as influenza, Ebola, cardiovascular disease, obesity, cancer, peripheral and central neurodegeneration. With the Operetta CLS, multiple parameters can be captured simultaneously for evaluation of tool or drug candidates against known targets as well as for uncovering unknown new targets in the exploration of a biological problem. Added benefit is unbiased image acquisition and powerful data analysis. The Operetta CLS is positioned to critical new research tool to facilitate our extensive basic or clinical research programs, which are attempting to understand and find treatments for human diseases.

项目总结/文摘

项目成果

Network model-based screen for FDA-approved drugs affecting cardiac fibrosis.

• DOI: 10.1002/psp4.12599
• 发表时间: 2021-04
• 期刊: CPT: pharmacometrics & systems pharmacology
• 作者: Zeigler AC;Chandrabhatla AS;Christiansen SL;Nelson AR;Holmes JW;Saucerman JJ
• 通讯作者: Saucerman JJ

Cutting down the time to identify challenging tumor therapeutic targets and drug combinations using synthetic lethal approaches.

使用合成致死方法缩短确定具有挑战性的肿瘤治疗靶点和药物组合的时间。

• DOI: 10.12688/f1000research.13679.1
• 发表时间: 2018
• 期刊: F1000Research
• 作者: Lazo,JohnS

High content screening miniaturization and single cell imaging of mature human feeder layer-free iPSC-derived neurons.

• DOI: 10.1016/j.slasd.2022.10.002
• 发表时间: 2023-09
• 期刊: SLAS DISCOVERY
• 影响因子: 3.1
• 作者: Sharlow, Elizabeth R.;Llaneza, Danielle C.;Grever, William E.;Mingledorff, Garnett A.;Mendelson, Anna J.;Bloom, George S.;Lazo, John S.
• 通讯作者: Lazo, John S.